192 related articles for article (PubMed ID: 38611025)
1. Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM; Osorio RC; Francois RA; Tawil ME; Tsai KK; Tetzlaff M; Daud A; Vasudevan HN
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611025
[TBL] [Abstract][Full Text] [Related]
2. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
6. Clinical Application of Next-Generation Sequencing-Based Panel to
Park C; Kim M; Kim MJ; Kim H; Ock CY; Keam B; Kim TM; Kim DW; Kim JI; Heo DS
Mol Cancer Ther; 2020 Mar; 19(3):937-944. PubMed ID: 31826932
[TBL] [Abstract][Full Text] [Related]
7. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
[TBL] [Abstract][Full Text] [Related]
8. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract][Full Text] [Related]
9. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.
Andrews MC; Li G; Graf RP; Fisher VA; Mitchell J; Aboosaiedi A; O'Rourke H; Shackleton M; Iddawela M; Oxnard GR; Huang RSP
JCO Precis Oncol; 2024 Jun; 8():e2300640. PubMed ID: 38848517
[TBL] [Abstract][Full Text] [Related]
10. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
11. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract][Full Text] [Related]
12. Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma.
Zablocka T; Kreismane M; Pjanova D; Isajevs S
Oncol Lett; 2023 Jan; 25(1):27. PubMed ID: 36478905
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.
Zaremba A; Mohr P; Gutzmer R; Meier F; Pföhler C; Weichenthal M; Terheyden P; Forschner A; Leiter U; Ulrich J; Utikal J; Welzel J; Kaatz M; Gebhardt C; Herbst R; Sindrilaru A; Dippel E; Sachse M; Meiss F; Heinzerling L; Haferkamp S; Weishaupt C; Löffler H; Kreft S; Griewank K; Livingstone E; Schadendorf D; Ugurel S; Zimmer L
Eur J Cancer; 2023 Jul; 188():140-151. PubMed ID: 37245442
[TBL] [Abstract][Full Text] [Related]
14. Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature.
Chłopek M; Lasota J; Thompson LDR; Szczepaniak M; Kuźniacka A; Hińcza K; Kubicka K; Kaczorowski M; Newford M; Liu Y; Agaimy A; Biernat W; Durzyńska M; Dziuba I; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kato H; Kopczyński J; Michal M; Michal M; Pęksa R; Prochorec-Sobieszek M; Starzyńska A; Takahashi S; Wasąg B; Kowalik A; Miettinen M
Mod Pathol; 2022 Nov; 35(11):1609-1617. PubMed ID: 35978013
[TBL] [Abstract][Full Text] [Related]
15. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
16. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.
Lodde GC; Jansen P; Möller I; Sucker A; Hassel JC; Forschner A; Eckardt J; Meier F; Reinhardt L; Kähler KC; Ziemer M; Schlaak M; Rahimi F; Schatton K; Meiss F; Gutzmer R; Pföhler C; Terheyden P; Schilling B; Sachse M; Heppt MV; Sindrilaru A; Leiter U; Zaremba A; Thielmann CM; Ugurel S; Zimmer L; Hadaschik E; Bechrakis NE; Schadendorf D; Westekemper H; Livingstone E; Griewank KG;
Eur J Cancer; 2022 May; 166():60-72. PubMed ID: 35279471
[TBL] [Abstract][Full Text] [Related]
17. Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
Kodali N; Bhattaru A; Blanchard I; Sharma Y; Lipner SR
Melanoma Res; 2024 Mar; ():. PubMed ID: 38564430
[TBL] [Abstract][Full Text] [Related]
18. Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.
Gkiala A; Palioura S
Clin Ophthalmol; 2020; 14():3137-3152. PubMed ID: 33116365
[TBL] [Abstract][Full Text] [Related]
19. Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients.
Lally SE; Milman T; Orloff M; Dalvin LA; Eberhart CG; Heaphy CM; Rodriguez FJ; Lin CC; Dockery PW; Shields JA; Shields CL
Ophthalmology; 2022 Jun; 129(6):679-693. PubMed ID: 35085662
[TBL] [Abstract][Full Text] [Related]
20. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]